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Aims: Extracellular ATP and ADP regulate diverse inflammatory, prothrombotic and
vasoactive responses in the vasculature. Statins have been shown to modulate their
signaling pathways in vitro. We hypothesized that altered intravascular nucleotide turnover
modulates vasodilation in patients with type 1 diabetes (T1DM), and this can be partly
restored with pravastatin therapy. Methods: In this randomized double blind study,
plasma ATP and ADP levels and echocardiography-derived coronary flow velocity response
to cold pressor test (CPT) were concurrently assessed in 42 normocholesterolemic
patients with T1DM (age 30 ± 6 years, LDL cholesterol 2.5 ± 0.6mmol/L) before and
after four-month treatment with pravastatin 40mg/day or placebo (n = 22 and n = 20,
respectively), and in 41 healthy control subjects. Results: Compared to controls, T1DM
patients had significantly higher concentrations of ATP (p < 0.01) and ADP (p < 0.01) and
these levels were partly restored after treatment with pravastatin (p = 0.002 and p =
0.007, respectively), but not after placebo (p = 0.06 and p = 0.14, respectively). Coronary
flow velocity acceleration was significantly lower in T1DM patients compared to control
subjects, and it increased from pre- to post-intervention in the pravastatin (p = 0.02), but
not in placebo group (p = 0.15). Conclusions: Pravastatin treatment significantly reduces
circulating ATP and ADP levels of T1DM patients, and concurrently improves coronary flow
response to CPT. This study provides a novel insight in purinergic mechanisms involved in
pleiotropic effects of pravastatin.
Keywords: ATP, ADP, soluble nucleotidases, coronary flow, pleiotropic effect
INTRODUCTION
Extracellular ATP and ADP are important signaling molecules
regulating diverse signaling responses in cardiovascular, nervous
and other systems (Ralevic and Burnstock, 1998; Bours et al.,
2006; Erlinge and Burnstock, 2008). Released into extracellu-
lar fluids by exocytosis from nucleotide-containing granules,
by efflux through a membrane transport system in response
to cell activation, or as a consequence of cell death, they act
as paracrine or autocrine mediators of inflammation (Bours
et al., 2006). Moreover, they cause vasodilation via selective
activation of a series of G-protein-coupled (P2Y) or ligand-
gated (P2X) receptors (Ralevic and Burnstock, 1998; Erlinge
and Burnstock, 2008; Mercier et al., 2012). ATP may stimu-
late vascular smooth muscle cell (VSMC) growth, migration,
release of matrix metalloproteinases and osteopontin that may
contribute to the development of diabetic microvascular disease
(Erlinge and Burnstock, 2008). Abnormal reactive hyperemia as
assessed with flow-mediated dilation (FMD) of brachial artery
(Järvisalo et al., 2004) or abnormal coronary microcirculatory
reactivity (Pitkänen et al., 1998) exists in patients with type
1 diabetes (T1DM) before any clinical signs or symptoms of
macrovascular disease. The role of purinergic signaling cascade
in the regulation of arterial vasodilation in the early stages
of atherosclerosis of patients T1DM, however, remains largely
unknown.
Statins activate the phosphoinositol-3 kinase and Akt sig-
naling pathway, and in addition, increase expression and activ-
ity of endothelial enzymes such as nitric oxide synthase,
cyclooxygenase-2 and ecto-5′-nucleotidase (Laufs et al., 1998;
Ledoux et al., 2002; Merla et al., 2007). Ecto-5′-nucleotidase
mediates rapid dephosphorylation of ATP/ADP-derived AMP
further to adenosine, which has vasodilatory, anti-inflammatory
(Bours et al., 2006) as well as cardioprotective responses against
hypoxia (Eltzschig et al., 2003). The ability of atorvastatin to
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up-regulate ATPase, ADPase and ecto-5′-nucleotidase (AMPase)
activities in human valve interstitial cells (Osman et al., 2006) sug-
gests that the whole purinergic cascade could bemodulated under
the action of statins.
The aims of this trial were (1) to perform comprehensive
comparative analysis of circulating ATP and ADP levels, solu-
ble nucleotidase activities, coronary flow responses to CPT in
control healthy subjects vs young asymptomatic, normocholes-
terolemic patients with non-complicated T1DM, and (2) to assess
whether these biochemical and hemodynamic parameters would
be concurrently modulated in T1DM patients in a prospec-
tive randomized placebo controlled four-month treatment with
pravastatin.
MATERIALS AND METHODS
PATIENT SELECTION AND STUDY DESIGN
Forty-two patients with non-complicated T1DM participated in
the study. The inclusion criteria were: age 18–40 years, diabetes
duration 3–25 years, no symptoms or diagnosis of cardiovascular
disease or asthma, no use of cardiovascular medication or
antioxidants, no diagnosis of proliferative retinopathy, FMD of
the brachial artery less than 10%, HbA1c less than 10%, LDL
cholesterol less than 4.0mmol/L and normal liver function.
Altogether 57 patients were screened for the study. The patients
were recruited by advertisement and from diabetes clinics in
Turku and surrounding areas. The patients were interviewed for
medical history, alcohol and caffeine use, physical activity and
family history of premature coronary artery disease. In addition,
serum human chorionic gonadotropin level was measured from
all female patients to exclude pregnancy. The subjects were
randomized in a double blind manner to receive either pravas-
tatin 40mg/day (n = 22) or placebo (n = 20) for four months.
Bristol-Myers Squibb, Finland, provided Pravastatin 40mg tablets
and matching placebos. In order to control for use of dietary
fats, the use of bread spread was standardized by providing all
subjects margarine (total fat content 60 g/100 g whereof 18 g satu-
rated, 29 g monounsaturated and 13 g polyunsaturated, vitamin E
12mg/100 g, vitamin A 900μg/100 g and vitamin D 7.5μg/100 g)
and advising to use 20 g/day of this product on bread. Otherwise
the subjects were advised to adhere to their normal diet. The
control group consisted of 41 healthy (mean age 24 ± 2.3 years)
normocholesterolemic, non-hypertensive, and non-smoking
Caucasian men.
The Local Ethical Committee of the Turku University Hospital
approved the study protocol. The study was conducted accord-
ing to the principles expressed in the Declaration of Helsinki. The
study protocol and the potential risks of the study were explained
in detail to the patients and thereafter a written informed consent
was obtained.
Blood samples were taken after an overnight fast on study
mornings from the antecubital vein. Blood was collected into
tubes for preparing plasma and serum blood samples, respec-
tively. For serum preparation, blood was allowed to clot before
centrifugation (10min at 1500 g) while plasma samples (EDTA)
were immediately centrifuged and freezed at −80◦C. Serum
lipid levels, HbA1c were determined as previously reported
(Janatuinen et al., 2004).
QUANTIFICATION OF ATP AND ADP LEVELS IN HUMAN PLASMA
Plasma ATP and ADP were determined by enzyme-coupled
assay using ATPlite assay kit with a long-lived luminescent sig-
nal (Perkin Elmer, Groningen, The Netherlands) as described
elsewhere (Mercier et al., 2012). Briefly, 10-μl aliquots of
EDTA-plasma from healthy as well as placebo and pravastatin-
treated T1DM were transferred into two parallel wells of
white non-phosphorescent 96-well microplate containing 100μl
PBS with (A) or without (B) mixture of 200μM UTP and
5U/ml of NDP kinase from baker’s yeast S. cerevisiae (Sigma).
Subsequent to addition of 50μl ATP-monitoring reagent contain-
ing luciferin/luciferase mixture, luminescence of the samples was
measured using Tecan Infinite M200 microplate reader (Salzburg,
Austria). The differences in luminescence signals between well
“A” (ATP + ADP) and “B” (only ATP) allowed quantifying the
concentration of ADP, which was converted into ATP through
the NDP kinase mediated reaction in the presence of exoge-
nous UTP. Such approach allows simultaneous measurement of
both ATP and ADP content within the same sample. Plasma
haemoglobin concentration was also determined by measuring
the absorbance at the peak of the Soret band (415 nm) and also
at 380 and 450 nm, as described previously (Mercier et al., 2012).
Hemoglobin levels in all analyzed blood samples did not exceed
4.0mg/dL (data not shown).
MEASUREMENT OF SOLUBLE NUCLEOTIDASE ACTIVITIES
Soluble NTPDase and 5′-nucleotidase activities were assayed
radiochemically, as described earlier (Yegutkin et al., 2007).
Specifically, for ADPase/NTPDase activity, serum (10μl)
was incubated 60min at 37◦C in 80μl RPMI-1640 medium
containing 5mM β-glycerophosphate, 80μM of adeny-
late kinase inhibitor Ap5A and 50μM ADP with tracer
[2,8-3H]ADP (Perkin Elmer, Boston, USA). Likewise, 5′-
nucleotidase activity was assayed by incubating 10μl serum
for 60min at 37◦C in 80μl RPMI-1640 with 5mM β-
glycerophosphate, 300μM [2-3H]AMP (Quotient Bioresearch,
GE Healthcare, Rushden, UK). Aliquots of the mixture (8μl;
∼ 5 × 105 dpm/spot) were applied to Alugram SIL G/UV254
sheets (Macherey-Nagel, Duren, Germany) and separated by
thin-layer chromatography using appropriate solvent mixture
(Yegutkin and Burnstock, 1998). Radiolabeled substrates and
their dephosphorylated products were quantified by scintilla-
tion β-counting and nucleotidase activities were expressed as
nanomoles of 3H-substrate metabolized per hour by 1ml serum.
Physiological variability of circulating nucleotide levels and
soluble nucleotidase activities were assessed in three males and
three females. Blood samples were collected after overnight fast-
ing week apart three times. Coefficients of variation were 0.47,
0.47, 0.18, and 0.27 for ATP, ADP, NTPDase, and 5′-nucleotidase,
respectively.
ECHOCARDIOGRAPHYPROTOCOL
Transthoracic echocardiography studies were performed with
Sequoia C 512 ultrasound mainframe (Acuson Inc., Mountain
View, California, USA) with a standard 3.5MHz transducer
as previously described (Kiviniemi, 2008). B-mode and color-
Doppler mapping were used to identify the distal LAD.
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The coronary flow velocity was assessed with a pulsed wave
Doppler and mean diastolic flow velocities (MDV) were
measured.
COLD PRESSOR TEST
The studies were performed after overnight fasting. Alcohol and
caffeine were prohibited 12 h before the study. On the study
morning, the subjects took one-half of their normal long-acting
insulin and no short-acting insulin. Baseline values of coronary
flow velocity were detected as an average of three separate flow
velocity measurements. After the baselinemeasurements, the sub-
jects’ right hand was placed into ice-cold water for 120 s. During
the hand immersion, flow velocity was measured continuously
to allow time course sampling of MDV values as previously
described (Kiviniemi et al., 2007). The hyperemia/baseline-ratio
of MDV during CPT, the time to the peak MDV during CPT
from 0 s time point and the average acceleration slope to the peak
were measured as previously described (Dimitrow et al., 2000).
The response profiles related to time to peak MDV and acceler-
ation slope to the peak were based on mathematical imputation
using non-parametric regression which can give reliable results
for reasonable amount of available observations. Profiles with less
than 20% data points available throughout the CPT have been
discarded to improve the quality of findings. Therefore, adequate
coronary flow velocity tracings could be obtained in 14 and 17
patients in pravastatin and placebo groups, respectively. This was
due to patients were moving during cold pressor test (CPT) hand
immersion.
CPTwas generallywell tolerated. Intra and inter-observer vari-
abilities of the CPT measurement (hyperemia to baseline ratio)
were coefficient of variation (CV) 3.0 ± 2.0%, and 3.7 ± 3.7%
respectively, and mean difference 0.0 (−0.1 to 0.1) and 0.0 (−0.2
to 0.2), respectively.
STATISTICAL ANALYSES
Results are presented as mean value ± SD unless stated otherwise.
Primary prospectively determined endpoint of CPT response
included hyperemia to baseline ratio, and co-primary end points
the time to the peak MDV during CPT from 0 s time point,
and the average acceleration slope to the peak (Dimitrow et al.,
2000). Sample size of 16 subjects was calculated for each group
with a known SD of 0.5 for CPT hyperemia to baseline ratio
and an assumed difference of 0.5 between the interventions
(α = 0.05, β = 0.80). ATP, ADP levels, and soluble NTPDase
and 5′-nucleotidase activity determinations and their association
with CPT values were assessed on a post hoc basis. Comparisons
between the groups were analyzed using the non-parametric
Mann–Whitney U-test, sign test and Wilcoxon signed-rank tests,
or using the parametric unpaired Student’s t-test where appro-
priate. For comparison between pre- and post-intervention levels
in the same group, paired t-test was used where appropriate.
Associations between the study variables were assessed using
the Pearson’s correlation coefficient. A p-value of <0.05 was
interpreted as statistically significant. Statistical analyses were per-
formed using SAS statistical program package (SAS Institute,
Cary, NC, USA) and Matlab (The MathWorks, Inc., Natick,
MA, USA).
RESULTS
SUBJECT CHARACTERISTICS
The analysis is based on the data from 42 diabetic patients.
The baseline characteristics of the study subjects are listed in
Tables 1 and 2. There were 13 smokers in the study group (7 and
6 in pravastatin and control groups, respectively). Compliance
determined by capsule count exceeded 90%. The study subjects
reported no side effects during pravastatin treatment. In one sub-
ject receiving pravastatin an asymptomatic rise in serum creatine
kinase level was detected at the follow-up visit. The level returned
to normal within 2 weeks after cessation of medication. As a
marker of glycemic control GHbA1c levels remained unchanged
during the intervention in pravastatin and placebo groups.
EFFECT OF PRAVASTATIN TREATMENT ON CIRCULATING NUCLEOTIDE
LEVELS AND SOLUBLE NUCLEOTIDASE ACTIVITIES
As shown in Figure 1, there were no significant differences in ATP
(panel A) and ADP (panel B) concentrations between pravas-
tatin and placebo groups before intervention. Noteworthy, both
nucleotides were maintained at significantly higher levels in
plasma from diabetic patients, as compared to healthy control
group.
After intervention, ATP and ADP levels decreased signif-
icantly in pravastatin group compared to pre-intervention
(p = 0.002 and p = 0.007, respectively), but not in the placebo
group (p = 0.06 and p = 0.14, respectively). Post-intervention,
the ATP and ADP levels were also significantly lower in pravas-
tatin group compared to the placebo group (p = 0.02 and
p = 0.03, respectively), while there was no difference during pre-
intervention (p = 0.55 and p = 0.50, respectively). No signs of
haemolysis or differences in plasma hemoglobin were detected
among the studied groups.
Since extracellular nucleotide levels generally represent a net
balance between nucleotide release and inactivation, we also
Table 1 | Baseline characteristics of the study subjects and healthy
control subjects.
Pravastatin Placebo Healthy
group group controls
N 22 20 41
Age (years) 30.2 ± 5.6 28.9± 6.5 24 ± 2.3
Males/females 13/9 11/9 41/0
Diabetes duration (years) 13.2± 7.8 10.5 ± 5.3 0
BMI (kg/m2) 24.7 ± 2.5 24.6± 2.6 24.2± 2.8
FMD (%) 3.4 ± 3.1 4.9 ± 3.1 N/A
Family history of CAD 4/22 2/20 N/A
Current smokers 7/22 6/20 0/41
Background retinopathy 5/22 3/20 N/A
Autonomic neuropathy 1/22 2/20 N/A
U-Albumin/creatinine
male > 2.5mg/mmol
female > 3.5mg/mmol
3/22 0/20 N/A
FMD, flow-mediated vasodilation of brachial artery; CAD, coronary artery dis-
ease; N/A, data not available.
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Table 2 | Glycemic control and lipid profile of the study subjects before and after treatment, and healthy control subjects.
Pravastatin (n = 22) Placebo (n = 20) Healthy control
Baseline Follow-up Baseline Follow-up (n = 41)
HbA1c(%) 8.3 ± 1.1 8.4 ± 1.2 8.2 ± 1.1 8.0 ± 1.1 N/A∗
Total cholesterol (mmol/L) 4.4 ± 0.5 3.3 ± 0.4∗∗ 4.6 ± 0.8 4.3 ± 0.6 4.2 ± 0.7
LDL cholesterol (mmol/L) 2.4 ± 0.5 1.6 ± 0.4∗∗ 2.5 ± 0.6 2.4 ± 0.6 2.3 ± 0.6
HDL cholesterol (mmol/L) 1.6 ± 0.3 1.5 ± 0.3 1.5 ± 0.3 1.5 ± 0.3 1.5 ± 0.4
Triglycerides (mmol/L) 0.8 ± 0.3 0.6 ± 0.2 1.3 ± 1.0 0.9 ± 0.5 0.9 ± 0.4
N/A = data not available. ∗ Reference range in non-diabetic subjects 4.2–6.0%; ∗∗p < 0.001.
FIGURE 1 | Effect of pravastatin treatment on circulating nucleotide ATP (A) andADP (B) levels and soluble nucleotidaseADPase (C) and 5′-nucleotidase
activities (D) in type 1 diabetic patients (pravastatin n = 22, placebo n = 20). Control refers to healthy subjects (n = 41). ∗p < 0.05; ∗∗p < 0.01.
determined, whether the activities of purinergic enzymes are
concurrently shifted in the bloodstream of the diabetic patients.
Since correct determination of serum ATPase is complicated
by co-existence of two different enzymes possessing nucleotide
hydrolase and pyrophosphatase activities (Yegutkin et al., 2007),
soluble NTPDase was assayed in the presence of specific adeny-
late kinase inhibitor Ap5A by using [3H]ADP as another pre-
ferred substrate. The results unambiguously showed that the
activities of serum NTPDase (Figure 1C) as well as another
nucleotide-inactivating enzyme 5′-nucleotidase (Figure 1D) did
not change in either group. Interestingly, the rate of [3H]ADP,
but not [3H]AMP, hydrolysis by serum from diabetic patients
was significantly lower in comparison with control group
(Figures 1C,D).
CORONARY FLOW VELOCITY RESPONSE TO COLD PRESSOR TEST
Adequate coronary flow velocity profiles were available for 14
and 17 patients in pravastatin and placebo groups, respectively.
Baseline flow velocity, hyperemia/baseline-ratio of flow velocity
during CPT and time to the peak flow velocity during CPT are
presented in Table 3. The acceleration to the peak flow velocity
value increased in the pravastatin group from pre- to post-
intervention (p = 0.02), but not in the placebo group (p = 0.15).
It was also marginally different (p = 0.05) between the pravas-
tatin and placebo groups post-intervention, but not at baseline
(p = 0.9).
Baseline flow velocity and the acceleration to the peak flow
velocity values were associated with post-intervention ATP levels
but hyperemia to baseline ratio was not (Figure 2, panel A–C).
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FIGURE 2 | Figure shows correlation graph of post-intervention baseline coronary flow velocity (A) (n = 27), CPT flow velocity/baseline flow velocity
(B) (n = 26) and acceleration to the peak slope (C) (n = 26) vs. post-intervention ATP value.
No association was seen with corresponding values and the
ADP levels.
DISCUSSION
The novel findings of this double blinded prospective con-
trolled trial in patients with T1DM are that, in comparison
with placebo group, four-month pravastatin treatment is accom-
panied by (1) significantly decreased levels of intravascular
ATP and ADP without any shifts in soluble nucleotidase activ-
ities; and (2) slightly improved coronary flow responses to
CPT. Moreover, T1DM patients had significantly higher plasma
nucleotide concentrations in comparison with healthy controls.
The obtained data on correlation between the elevated plasma
ATP and ADP levels and impaired CPTmight suggest the implica-
tion of purinergic signaling mechanisms in beneficial pleiotropic
effects of statins in T1DM patients.
Striking novelty of this study is that, compared to healthy
subjects, patients with T1DM had higher circulating ATP and
ADP levels at the fasting state and this increment can be
partially restored after 4-month treatment with pravastatin.
The exact mechanisms underlying the elevated pre-intervention
nucleotide levels in T1DM patients remain unknown and
might be particularly defined by enhanced ATP release from
endothelial cells in response to chronic hyperglycemia (Parodi
et al., 2002); increased shear stress due to disturbed blood
flow (Yegutkin et al., 2000, 2007); and/or by diminished activ-
ity of vascular endothelial NTPDase/CD39 (Robson et al.,
2005). In line with the altered nucleotide turnover results,
we recently provided evidence of increased levels of circulat-
ing ATP and ADP as well as impaired coronary vasodilation
response in young pre-atherosclerotic apolipoprotein E-deficient
mice versus wild type littermates (Mercier et al., 2012). An
increase in glucose from 5 to 15mmol/l results in a marked
increase in the proatherogenic nuclear factor of activated T
cells signaling pathway in VSMC (Nilsson et al., 2006). The
effect is mediated via glucose-induced release of ATP and
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UTP, which subsequently activate P2Y2 but also P2Y6 receptors
after degradation to UDP. Thus, nucleotide release is a poten-
tial metabolic sensor for the arterial smooth muscle response
to high glucose. (Erlinge and Burnstock, 2008) In this con-
text, it is relevant to emphasize that serum NTPDase activ-
ities were lower in diabetics, as compared to those of the
healthy control group. Moreover, while no significant shifts in
soluble nucleotidase activities were detected in the sera from
pravastatin-treated T1DM patients versus placebo group, we
do not exclude the possibility of statin-mediated up-regulation
of vascular nucleotidase activities, which in turn would affect
the levels of circulating nucleotides and tune their signaling
responses in the cardiovascular system. This hypothesis is indi-
rectly supported by previous in vitro data on the ability of
various statins (lovastatin, atorvastatin) to increase the activi-
ties of ecto-5′-nucleotidase (Ledoux et al., 2002; Sanada et al.,
2004; Osman et al., 2006) and other nucleotide-inactivating
enzymes (Osman et al., 2006) in vascular endothelial and other
cells. Irrespective of the underlying mechanisms, the incre-
ment of plasma ATP and ADP in T1DM patients and their
decrease after pravastatin treatment would reasonably suggest
that a net balance between nucleotide release and inactivation
is disturbed in diabetes and it can be partially restored by
statins.
This is the first study assessing the role of purinergic
signaling molecules in the early stages of coronary microcir-
culatory dysfunction of T1DM patients without any clinical
signs or symptoms of macrovascular disease or microvas-
cular complications. Due to small sample size, the physio-
logical responses to CPT need to be interpreted cautiously.
The primary end point—hyperemia to baseline ratio—was not
significantly altered, and there was only a slight statistically
non-significant increase in baseline flow velocity after pravas-
tatin treatment in T1DM patients. The co-primary end point
(acceleration slope to the peak and time to peak flow) differ-
ences were more obvious though subtle between the pravastatin
and placebo groups. Compared to healthy men, pre-intervention
hyperemic flow response was lower in T1DM patients in terms
of lower peak flow velocity and longer acceleration time to
peak.
We intentionally selected subjects with normal cholesterol
levels and good to satisfactory glycemic control who are
likely to be representative of the majority of young patients
with type 1 diabetes not generally receiving lipid-lowering
therapy although being in clearly increased risk in develop-
ing CAD. At the time of the recruitment the study subjects
had no diagnoses of diabetic complications other than back-
ground retinopathy and microalbuminuria in a small number
of the subjects. Autonomic neuropathy in type 1 diabetes
has been suggested to cause hyper-reactivity to nitro vasodila-
tors in the forearm vasculature (Mäkimattila et al., 1997).
Therefore we did not include subjects with FMD of the
brachial artery more than 10% in the study. Pravastatin treat-
ment was generally well tolerated and did not worsen glycemic
control. Despite the physiological variability of enzymatic
activities/nucleotide concentrations for each individual was
relatively high (within 18–47%), there was a distinct differ-
ence in ATP and ADP levels between T1DM patients and
the control group pre-intervention. Moreover, the decrease in
ATP levels after intervention was greater than the physiological
variability.
Some limitations need to be addressed. Firstly, caffeine—a
competitive adenosine receptor antagonist—was withdrawn 12 h
before blood sample collection, and CPT and FMD tests. It is
possible that some of its effect persisted at the time of test-
ing. Secondly, we measured soluble ADPase and 5′-nucleotidase
activities, but also other methods of nucleotidase activity assess-
ment have been reported. In a recent report, the effect of
rosuvastatin treatment on ecto-5′-nucleotidase activity on the
surface of human mononuclear cells was measured and its
up-regulation further correlated with vasodilatory responses to
ischemia (Meijer et al., 2010). Nevertheless, this rather het-
erogenous cell population represents only certain fraction of
circulating hematopoietic cells and express relatively low ecto-
5′-nucleotidase activity as compared to vascular endothelial cells
(Yegutkin et al., 2002), with the latter cells being generally
considered the major regulators of intravascular purinergic sig-
naling and hyperaemic responses. From this point of view, we
believe that soluble serum 5′-nucleotidase—in conjunction with
another key inactivating enzyme NTPDase1/CD39—represents
more integrative parameter of systemic shifts in the enzyme lev-
els and might open up further research to assess the potential
diagnostic application of purine-converting enzymes in clinical
biochemistry.
CONCLUSIONS
Intravascular nucleotide turnover is altered in the early stages of
atherosclerosis in T1DM patients as compared to healthy con-
trol subjects. Four-month treatment with pravastatin in young
normocholesterolemic patients with non-complicated type 1
diabetes decreased circulating ATP and ADP levels and con-
currently improved coronary microvascular reactivity to CPT
as compared to placebo. The existence of correlation between
intravascular ATP and ADP and coronary reactivity also indi-
cates on the physiological relevance of the measured sys-
temic nucleotide levels and may open up further research
for future therapeutic or diagnostic applications of puriner-
gic signaling pathways in the treatment of diabetes and other
diseases.
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